Lundbecks Vyepti
Feb 25, 2020
US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing
Formerly known as eptinezumab, Lundbeck’s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine. With the gree...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
